Payment overview · 2025
General Payments
$865.64
27 reported records · 7 companies
Healthcare provider profile · identity verified
Cyriac Thomas Thachet, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1578547709
Verified facts
What the public records show
CMS Open Payments records show Cyriac Thomas Thachet, MD received $865.64 in general payments during 2025 across 27 reported records.
GlaxoSmithKline, LLC. accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $282.64 | 32.6% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $220.93 | 25.5% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.14 | 13.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $111.94 | 12.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $89.88 | 10.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.09 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.02 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $865.64 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $193.83 | 5 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $180.77 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $113.14 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $111.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $89.88 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $88.81 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.93 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 887 | 222 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 594 | 109 |
| Omeprazole | Omeprazole | 560 | 105 |
| Lisinopril | Lisinopril | 481 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 470 | 102 |
| Gabapentin | Gabapentin | 451 | 75 |
| Metformin Hcl | Metformin Hcl | 431 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 400 | 99 |
| Furosemide | Furosemide | 395 | 86 |
| Ibuprofen | Ibuprofen | 386 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 60 |
| Trazodone Hcl | Trazodone Hcl | 265 | 43 |
| Tramadol Hcl | Tramadol Hcl | 248 | 43 |
| Famotidine | Famotidine | 214 | 43 |
| Sertraline Hcl | Sertraline Hcl | 211 | 32 |
| Eliquis | Apixaban | 210 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 206 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 203 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 26 |
| Clonazepam | Clonazepam | 197 | 30 |
| Losartan Potassium | Losartan Potassium | 192 | 48 |
| Lorazepam | Lorazepam | 188 | 31 |
| Alprazolam | Alprazolam | 187 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 179 | 44 |
| Simvastatin | Simvastatin | 177 | 39 |
| Montelukast Sodium | Montelukast Sodium | 168 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 32 |
| Alendronate Sodium | Alendronate Sodium | 147 | 31 |
| Carvedilol | Carvedilol | 142 | 30 |
| Metformin Hcl Er | Metformin Hcl | 140 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 34 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 131 | 44 |
| Naproxen | Naproxen | 123 | 22 |
| Xarelto | Rivaroxaban | 117 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 29 |
| Jardiance | Empagliflozin | 110 | 24 |
| Januvia | Sitagliptin Phosphate | 107 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 100 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 97 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 19 |
| Prednisone | Prednisone | 90 | 60 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 84 | 19 |
| Aripiprazole | Aripiprazole | 77 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 18 |
| Allopurinol | Allopurinol | 71 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 12 |
| Spironolactone | Spironolactone | 68 | 13 |
| Ezetimibe | Ezetimibe | 61 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 60 | 17 |
| Donepezil Hcl | Donepezil Hcl | 59 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 16 |
| Nifedipine Er | Nifedipine | 59 | 11 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | suppressed |
| Levetiracetam | Levetiracetam | 53 | 11 |
| Mirtazapine | Mirtazapine | 53 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 50 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Meloxicam | Meloxicam | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 47 | 16 |
| Potassium Chloride | Potassium Chloride | 47 | 11 |
| Endocet | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Atenolol | Atenolol | 44 | 12 |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 41 | 17 |
| Spiriva Handihaler | Tiotropium Bromide | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Valsartan | Valsartan | 35 | 14 |
| Azithromycin | Azithromycin | 34 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 20 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ultracare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $865.64 · 27 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, ENTRESTO, FARXIGA, JARDIANCE, LEQVIO, LOKELMA, NURTEC ODT, PREVNAR 20, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error